TITLE: A systematic review and modelling insights of factors impacting measles vaccine effectiveness

SHORT TITLE: Factors impacting measles vaccine effectiveness

AUTHORS: Samiran Ghosh, PhD[1,*]; Divya Kappara, PhD[2,*]; Nabanita Majumder, PhD[2,*]; Suchita Nath-Sain, PhD[2,*]; Arup Deb Roy[3]; Siuli Mukhopadhyay, PhD[1,2]

*Contributed equally to the work

AFFILIATIONS:

[1]Department of Mathematics, Indian Institute of Technology, Bombay, Mumbai-400076, Maharashtra, India

[2]National Disease Modelling Consortium, Indian Institute of Technology, Bombay, Mumbai-400076, Maharashtra, India

[3]JSI India, Nelson Mandela Marg, Vasant Kunj, New Delh-110070i, India

SG: Institute postdoctoral fellow, ghosh.samiran987@gmail.com, +91 7001849937
DK: Postdoctoral Associate, kapparadivya@gmail.com,+91 9848695130
NM: Senior Research Scientist, 30005801@iitb.ac.in, +91 9920882941
SNS: Senior Executive Officer, snsain,iitb@gmail.com, +91 98204 87553
ADR: John Snow, Inc, arup_debroy@in.jsi.com, +91 95600 67019

CORRESPONDING AUTHOR:

Prof. Siuli Mukhopadhyay
Professor
Department of Mathematics, Room - 204E
Indian Institute of Technology Bombay
Mumbai-400076, India
Email: siuli@math.iitb.ac.in
Telephone: 91-22-2576-7495

SYSTEMATIC REVIEW

NUMBER OF TABLES: Main text, 2; Supplementary materials, 4

NUMBER OF FIGURES: 4

FINANCIAL SUPPORT: Funding for this study was provided by the Gates Foundation (INV-044445)

ABSTRACT

Introduction

Outbreaks of measles have been frequently reported despite the availability of an effective vaccine. In this systematic review we examine the potential factors that could impact the effectiveness of the measles vaccine (MV) in children.

Methods

We conducted a literature search using PubMed and Google Scholar for primary articles published between January 2014 and July 2024. Articles reporting the effectiveness or immunogenicity of MV in children aged 0-15 years were included. Additionally, we use regression analysis on data available from few cohort studies in India and epidemiological modelling simulations to assess the effect of factors on vaccine effectiveness (VE).

Results

Overall, 34 primary articles involving 151888 children who had received the MV were included in the analysis. Key factors that may affect VE were malnutrition, genetic variants, chemotherapy and gender. Through statistical modelling we identified an inverse relationship between malnutrition and measles VE and estimated the possible percentage decrease in VE due to malnutrition across different states of India. Additionally, simulations from a Susceptible-Infected type model showed the effect of varying VE on the modelling outcomes and measles elimination targets.

Conclusions

We identified a few key factors including malnutrition, genetic variants, chemotherapy and gender that impact measles VE. Therefore, in addition to maintaining WHO recommended vaccine coverages, addressing the problems related to VE is crucial for achieving measles elimination targets.

Keywords: epidemiological modelling, malnutrition, measles, modelling, systematic review, vaccine effectiveness

INTRODUCTION

Measles is a highly contagious, vaccine-preventable viral disease transmitted by respiratory droplets, small particle aerosols, and close contact [1]. Each infection can cause 12-18 secondary cases among the at-risk population. According to recent estimates from the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), global measles cases reached approximately 10.3 million in 2023, marking a 20% rise compared to 2022 [2]. Due to gaps in vaccination coverage worldwide, 57 countries across the WHO African, Eastern Mediterranean, European, Southeast Asian, and Western Pacific regions witnessed a substantial upsurge in measles cases [2].

Vaccination against measles at the community level has been the most effective way to prevent the disease [3]. The World Health Organization (WHO) currently recommends administering the first dose of the vaccine at 9 months in areas where measles is common and at 12-15 months elsewhere. A second dose is recommended, usually at 15-18 months. Serologic evaluations have shown that the measles vaccine (MV) elicits immune responses in the majority of the susceptible population with median vaccine effectiveness (VE) of 84% for one dose and 94.1% for two doses [4].

Although an effective vaccine is available, measles virus remains an important cause of worldwide mortality and morbidity accounting for 107,500 deaths in 2023 [3]. While measles vaccination has prevented ~60 million deaths between 2000-2023, it is still a common disease in many parts of the world with yearly outbreaks. The majority of these deaths occur among children under the age of five, particularly in regions where vaccination coverage is low or inconsistent [5]. In 2023, measles

cases in Southeast Asian countries surged to 40.9 per million from 16.2 per million population in 2013 even though 91% of children received one dose and 85% received two doses of MV [6]. In India particularly, which report much higher measles vaccine (MV) coverage (93.35% for first dose, and 89.84% for two doses [6]) than the global or the South-East Asian coverages, several recent outbreaks have threatened the elimination efforts in the country. These high disease counts and repetitive outbreaks raise questions about the actual effectiveness of the MV [7, 8]. It is worrisome that such an effective [4] and high coverages were unable reduce the frequency of the measles outbreaks. As noted in the literature, the effectiveness of the MV has a crucial role to play in the prevention of outbreaks and successful control of the spread of the measles virus. Thus, any possibility of lowered vaccine effectiveness leading to these frequent outbreaks raises concerns regarding any country's progress toward elimination of the disease. Such observations motivate us to search and evaluate the effect of any underlying factors in the susceptible populations of such countries which may be affecting and lowering the VE, thus making them the population more vulnerable to the disease.

Vaccine effectiveness (VE), i.e the ability of vaccines to provide protection in real-world conditions [9], has been noted to vary in different populations, with lower estimates particularly in African [10] and South East Asian countries. Individual variation in the immune response to vaccination for several diseases including measles, have been reported widely in the literature [11-15]. Zimmerman et al [15] reported that an estimated 19 million measles vaccinated children have been left unprotected due to ineffectiveness of MV.

Given the paucity of research in this area, in this systematic review, our aim is to identify the important factors, which may be responsible for lowering the VE of MV in

children. Understanding and identifying these factors is essential for addressing the challenges posed by variations in vaccine performance across different populations. By identifying the socio-demographic and other contributory factors that may reduce the VE of MV, this review seeks to provide actionable insights for improving public health interventions. The findings of this review are expected to aid policymakers in tailoring disease control and elimination strategies, ensuring they account for regions or populations with suboptimal vaccine effectiveness. Additionally, we assess the effect of a key factor of VE using statistical tools and study the impact of varying VE on epidemiological model predictions through simulations. Variations in VE is shown to substantially effect model-generated estimates of disease burden.

METHODS

We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [16].

Search strategy

We searched PubMed and Google Scholar for primary articles published between January 2014 and July 2024. using Medical Subject Headings (MeSH) terminology for our population of interest including infants, preterm infants, premature birth, premature infants, children or adolescents; interventions including measles-mumps-rubella vaccine, MMR vaccine, pluserix, virivac, trimovax, triviraten berna, or priorix; and outcomes including VE, vaccine immunogenicity, or antibody response (**Table 1**). While our intention was to study VE in real-world conditions, this term has been used interchangeably with ‘vaccine efficacy’ or the effect of vaccines in controlled clinical trial settings [9]. Therefore, articles reporting both these terms were included.

Vaccine immunogenicity refers to the ability of vaccines to induce a measurable immune response [17]. The literature search was limited to articles reported in English. Additionally, articles were identified from websites as well as from references cited in review articles.

Table 1. Population, intervention, comparison, and outcome (PICO) framework

PICO Framework	
P (Population)	Children aged 0–15 years who have received the measles vaccine (MV)
I (Intervention)	Measles vaccine
C (Comparison)	Not applicable
O (Outcome)	The primary outcome of this systematic review is to identify the important factors that may be responsible for lowering the vaccine effectiveness (VE) of MV in children. Additionally, to assess the effect of a key factor of VE using statistical tools and study the impact of varying VE on epidemiological model predictions through simulations

Inclusion and exclusion criteria

Primary articles reporting the effectiveness or immunogenicity of MV in children aged 0-15 years were included. Narrative or systematic reviews, meta-analysis, book chapters, letters, as well as articles reporting other disease areas or not meeting the inclusion criteria were excluded.

Selection and data extraction

Articles retrieved from the databases were imported to EndNote 21. Duplicate articles were removed. The articles were independently screened by two authors based on titles and abstracts. Relevant data were extracted to a spreadsheet from the selected articles by two independent authors. Study-level information was

recorded in the spreadsheet, which included author names, year of publication, study period, study design, setting, sample size, age group, and factors impacting measles VE. Discrepancies regarding inclusion of individual articles were resolved by discussion with a third author.

Assessment of risk of bias

The risk of assessment was conducted by three independent authors using the Joanna Briggs Institute (JBI) Critical Appraisal tool [18] (Supplementary tables I-IV). Bias was assessed at the study, outcome, and result level. The tool has a specific number of questions for each study type (case-control, cohort, cross-sectional and randomised control trials). Each question is assessed by scoring (yes=1), (no=0) and (unclear or not applicable=0). Based on the total score, each study was categorised as high (20-49%), moderate (50-79%) or low (80-100%) risk. Risk of bias was assessed by three authors and discrepancies were resolved by consensus.

Statistical analysis

We utilised linear regression to assess the statistical relationships and a Susceptible-Infected (SI) model as described previously [19, 20], to simulate the scenario analysis. Data were processed and analysed using R for statistical modelling and MATLAB for the SI simulations. The spatial visualisations were created in R using publicly available geographic datasets from https://onlinemaps.surveyofindia.gov.in.

RESULTS

Study selection and characteristics

A total of 514 articles were retrieved from databases (PubMed, 334; Google Scholar, 180), of which 11 duplicates were excluded and 503 were screened based on

title/abstract (**Figure 1**). Of these, 460 articles were excluded as they were not primary articles or did not meet the prespecified inclusion criteria. The full-text for 1 article was unavailable leaving 42 articles for review. An additional 37 articles were identified from websites and cross-references of which 12 were considered for full-text review. After full-text review of a total of 54 articles, 20 articles were excluded as they were not primary articles or did not meet the inclusion criteria. Overall, 34 studies were included in the analysis.



Figure 1. PRISMA flow diagram

The studies were conducted in several countries including Australia, Brazil, Czech Republic, Democratic Republic of Congo, Guinea-Bissau, Italy, Kuwait, and United States. A total of 8 studies were conducted in Asia of which 1 was from India (**Table 2**). Most were cohort studies (n=15), followed by randomised controlled trials (RCTs; n=8), cross-sectional (n=6) and case-control studies (n=5). Community (number of studies=17) and hospital-based studies (n=7) were most common. The studies included 151888 children comprising 7329 infants (0-12 months).

Table 2. Study characteristics of the included articles

Author, year	Country	Study period	Study design	Study setting	Sample size	Age group	Factors affecting the effectiveness of measles vaccine
Bati et al, 2021	Ethiopia	2014	Case-control	Community	204	6-59 months	Age at first dose and Cold chain
Carryn et al, 2019	Czech Republic, Greece, Italy, Lithuania, Norway, Poland, Romania, Russian Federation, Slovakia and Sweden	2005-2006	Randomized controlled trial	Community	1887	12-22 months	Number of doses
Doshi et al, 2015	Democratic Republic of Congo	2010–2012	Case-control	Case-Based (CB) measles surveillance system with laboratory confirmation	2379	12-59 months	Malnutrition
Ferreira et al, 2018	Brazil	2007-2010	Cohort study	Clinic	121	12 months	Preterm birth
Ferreira et al, 2023	Brazil	2015-2016	Cohort study	Community	825	2 years	Malnutrition
Fouda et al, 2018	Saudi Arabia	2014-2017	Cross-sectional	Clinic	57	1-18 years	Treatment for comorbidities
Haralambieva et al, 2018	USA	2001-2011	Cohort study	Community	2872	11-40 years	Genetic variants
He at al, 2014	China	NA	Randomized controlled trial	Community	280	8, 12 months	Age at first dose
Jusko et al, 2019	USA	1999–2004	Cross-sectional	Community	7005	6-17 years	Toxins
Klein et al, 2021	USA	2018	Randomized controlled trial	Community	1736	12-15-month	Fever
Kontio et al, 2016	Finland	2013	Cohort study	Clinic	187	11-13, 17–19 months	Age at first dose
Martins et al, 2014	Guinea-Bissau	2003-2007	Randomized controlled trial	Community+Hospital	6417	4.5-36 months	Age at first dose
Martins et al, 2014	Guinea-Bissau	2003-2007	Randomized controlled trial	Community	900	4.5, 9, 18, and 24 months	Age at first dose
Mufson et al, 2015	USA	2009-2010	Randomized controlled trial	Community	1220	12-15 months	Vaccine strains
Pillsbury et al. 2015	Australia	2006-2012	Case-control	National Notifiable Diseases Surveillance System (NNDSS)	3987	1-15 years	Number of doses
Sánchez-Alemán et al, 2021	Mexico	2017	Cross-sectional	Community	416	6 to 13 years	Malnutrition
The MMR-158 Study Group, 2019	USA	NA	Randomized controlled trial	Community	3846	4-6 years	Vaccine strains
Zahraei et al, 2016	Iran	2013	Cohort study	Urban Health Centers	236	12 months	Malnutrition
Zimmermann et al, 2019	Australia	2013-2016	Randomized controlled trial	Community	471	7-13 months	Gender
Ferreira et al 2023	Brazil	2015-2016	Cohort study	Urban Area	1242	0-2 years	Malnutrition
Dhanorkar et al 2018	India	2018	Cross-sectional study	Rural area	NA	-	Cold chain management
Doshi et al. 2015	Democratic Republic of Congo (DRC).	2010-2012	Case Control Study	Community	2379	12-59 months	Malnutrition

Geier et al 2019	USA	1990-2009	Cohort study	Hospital	101736	120 months	Age at first dose
ZAHRAEI ET AL. 2016	Iran	2013	Cohort study	Urban Health Centers	270	12-12 months 30 days	Malnutrition
Wang et al 2022	China	2017-2019	Cohort study	Hospital	110	0.8-14.4 years	Treatment for comorbidities
Pittet et al. 2024	Switzerland	2013-2022	Cohort study	Hospital	119	3.4-13.4 years	Treatment for comorbidities
Ovsyannikova et al. 2014	USA	2001-2007	Cohort study	Community	764	11-18 years	Genetic variants
Bianchi et al 2020	Italy	2014-2018	Cohort study	Hospital	4563	All age groups	Age at first dose
Madi et al 2020	Kuwait	2017-2018	Cross-sectional study	Hospital	1000	5-20 years	Gender
Crom et al 2024	USA	2019-2022	Cohort study	Hospital	262	11-30 years	Treatment for comorbidities
Tomášková et al. 2018	Czechia	2013	Cross-sectional study	Community	3111	1-64 years	Age at first dose
Ghafoori et al 2024	Iran	2020	Cohort study	Laboratory	290	2-22 years	Gender
Musa et al. 2018	Bosnia and Herzegovina	2014-2015	Cohort study	Community	906	6-15 years	Number of doses
Koochakzadeh et al. 2014	Iran	2007-2008	Case Control Study	Hospital	90	2-16 years	Treatment for comorbidities

Several factors were reported to likely influence VE including age (n=8); malnutrition (n=7); comorbidities (n=5); gender, number of doses (n=6); fever, genetic factors (n=2); as well as cold chain management, preterm birth, vaccine strain and toxin (n=1).

Factors influencing VE

1. Malnutrition

Child malnutrition is an important global public health issue with significant implications [21]. The relationship between malnutrition and childhood diseases like measles is particularly crucial, highlighting the need for measles vaccination for malnourished children [22].

A 2016 study conducted in Southeast Iran found a significantly lower seroconversion rate among malnourished children. The study involved 270 infants aged 12-months with 236 completing both pre- and post-vaccination blood sampling phases. After receiving the measles–mumps–rubella (MMR) vaccine, the seroconversion rate was 91.2% (95% confidence interval [CI]: 86.7-94.5) indicating a protective response against measles. However, stunting (height-for-age z-score <-2) was strongly associated with a lack of seroconversion (odds ratio=5.6; 95%CI: 1.7-18.2) [23]. Similar conclusions were drawn from a study in the Democratic Republic of Congo, which highlighted a strong association between malnourishment and measles cases. This study also looked at the malnourished children suffering from malaria infection. Lower VE was observed in malaria-endemic countries where many children suffer from malnutrition [24]. In Southern Mexico, low anti-measles serologic coverage (59%) was reported to be associated with age (lower antibodies in 10- to 13-year-old

versus 6-year-old children), female sex, large family size (≥8 members), and underweight [25] Another study in Brazil found poverty and poor nutritional status to be closely associated with vaccine compliance and antibody positivity [26]. A study conducted in Eastern Mumbai slum areas in children with low nutritional status reported that VE was 64% (95%CI: 23-73%) and 70% (95%CI: 28-88%) for two doses among children <5 years and 5-15 years, respectively [27]. The above findings show a strong inverse relationship between malnutrition and VE.

2. Age at first dose

Several studies examined whether the age of administration of the first dose impacts VE. In a district of Ethiopia, although the vaccination coverage rate was 95%, the overall measles VE was only 70.9% (95%CI: 65-79%) [28]. Only 45.1% of children received the first dose at 9 months and 35.3% received a second dose after 12 months. A study in China involving 280 infants showed that administering the MMR vaccine at 8 months, provides comparable immunogenicity as vaccination at 12 months [29]. Similarly, in Finland, where the MMR vaccination age was lowered to 12 months, seropositivity rates and IgG antibody concentrations in 187 3-year-old children were similar regardless of whether children were vaccinated at 11-13 months or 17-19 months [30]. In contrast, a retrospective longitudinal cohort study involving 101736 children reported that administering the MMR vaccine at 16-20 months of age was linked to higher VE compared to 12-15 months of age [31]. Additionally, in a retrospective cohort study conducted in Italy, a significant proportion of immunised individuals did not retain protective levels of anti-measles IgG antibodies 10 years later [32]. This proportion was higher among those vaccinated ≤15 months (20%) compared to those vaccinated at 16-23 months (17%)

and ≥24 months (10%). In a study conducted in Guinea-Bissau, among 6417 children 77% had protective antibodies by 9 months after the first dose at 4.5 months. After a second dose at 9 months, 97% maintained antibody levels at 24 months. Among children who received MV at 9 months, 99% had antibody levels at 24 months even without a second dose at 18 months [33]. However, a cross-sectional study conducted in Pune, India, involving 600 children showed that despite receiving the MV at 9 months >25% of children became susceptible by 12-15 months [34].

3. Vaccine strains

MVs are live attenuated and derived from various strains, with globally used strains including Edmonston-Zagreb, Schwarz, Moraten, Leningrad-16, Hu-191 (Shanghai-191), CAM-70, TD-97 [35]. In India, the Edmonston-Zagreb and Schwarz strains are primarily used [36, 37]. The Hu-191 strain in the MMR vaccine achieved a 100% seropositivity rate for measles when the first dose was administered at 8 or 12 months [29], while the Edmonston-Zagreb strain reached up to 97% seropositivity for early vaccination at ≤6 months and 99% for the first dose at 9 months [33]. Mufson et al[38] evaluated the immunogenicity and safety of various MMR vaccine strains like Priorix™ (MMR-RIT) and MMRII. In a study of 1220 healthy children aged 12–15 months, results showed high seroresponse rates for both MMR-RIT (98.3-99.2%) and MMRII (99.6%) strains. Similarly, in an RCT[39] comparable immune responses was observed for the MMR-RIT (Priorix, GSK) and MMR II (M-M-R II, Merck & Co Inc.) vaccines when administered to 4011 children aged 4-6 years as a second dose, either alone or in combination with the DTaP-IPV and varicella vaccines. These findings suggest that the effect on VE is comparable between vaccine strains.

4. Fever

Fever is a common side effect following measles vaccination. Predictably, measles vaccination may induce fever in 5%-15% of vaccine recipients 7-10 days post-vaccination [40, 41]. Fever after vaccination may indicate an innate and/or cell-mediated immune response that precedes the humoral response [42].

A study found that the geometric mean titres (GMT) against measles in children without and with fever after MMR vaccination were 2918 (95%CI: 2318-3673) and 4609 (95%CI: 3629-5853), respectively [43]. These results suggest that fever following vaccination is strongly linked to a higher immune response.

5. Cold chain management

Cold-chain management is crucial for maintaining VE, particularly for temperature-sensitive vaccines like MV. While stable between -70°C and -20°C, the MV rapidly loses potency once reconstituted and exposed to higher temperatures, losing about 50% at 20°C in one hour and nearly all at 37°C [28]. Proper cold-chain management requires keeping vaccines at −20°C in national stores and 2-8°C at health facilities, with usage within 4 hours post-reconstitution [44, 45]. Failure to maintain these conditions can reduce VE, increasing the risk of outbreaks in areas with poor infrastructure [28].

6. Number of doses

Two doses of MV are recommended to ensure robust immunity and prevent outbreaks, as not all children develop immunity from the first dose [3]. According to the Center for Disease Control and Prevention (CDC), a single dose of MV is approximately 93% effective at preventing measles if exposed to the virus, while two

doses are approximately 97% effective [46]. An RCT conducted across several European countries examined the long-term effects of 1 and 2 doses of MMR-containing vaccines administered in the second year of life [47]. The study found that these vaccines induced antibody responses that persisted post-vaccination with high seropositivity rates even a decade later regardless of the vaccine administered and schedule. A cohort study conducted in the Federation of Bosnia and Herzegovina found that the effectiveness of MV was 91.9% (95%CI: 81.4–96.4%) for a single dose and 97.3% (95%CI: 95.5–98.4%) for two doses [48]. Another study in Australia assessed the effectiveness of MV at the population level using national notification data from 2006-2012 [49]. Analysing cases of measles in children born after 1996, the study found the estimated effectiveness of MV to be 96.7% (95%CI: 94.5–98.0%) and 99.7% (95%CI: 99.2–99.9%) for one and two doses, respectively. Overall, VE for ≥1 dose was 98.7% (95%CI: 97.9-99.2%) suggesting that two doses are more effective than one dose of MV.

7. Preterm birth

A prospective study compared the immune response to MV between infants born prematurely and those born at full term [50]. The study included 65 premature infants (birth weight <1500 g) and 56 full-term infants aged 12 months. The results showed that both groups had similar rates of immunity following vaccination (antibody levels: 2.393 vs. 2.412 UI/mL; p=0.970). Overall, the study concluded that humoral responses to measles did not vary among premature and full-term infants.

8. Toxins

A cross-sectional study in the US analysed the link between blood lead levels and antibody responses to measles, mumps, and rubella in 7005 children aged 6-17

years, using data from the 1999-2004 National Health and Nutrition Examination Survey [51]. Children with blood lead levels of 1-5 µg/dL had 11% (95%CI: -16, -5) lower anti-measles antibodies and were twice as likely to be seronegative for measles. This suggests that lead levels even below the CDC's 5 µg/dL action level may impair immune function and VE.

9. Genetic variants

A genome-wide association study was conducted in the USA focusing on measles-specific neutralising antibodies and IFNγ ELISPOT responses in 2872 subjects [52]. The findings revealed that common single-nucleotide polymorphisms (SNP) in the CD46 and IFI44L genes are associated with measles-specific humoral immunity. This study underscores the significance of studying the relationship of genetic variants to the inter-individual variation in immune response following live measles vaccination. Furthermore, a cohort study with 764 healthy children aged 11-18 (Caucasian-American, 80.6%; African-American, 11.6%) from Rochester, was conducted to measure the immune response to MV[53]. Post-vaccination immune responses was found to be associated with genetic polymorphism in the DDX58 gene (rs669260). Overall, variation in genes may lead to differences in VE.

10. Treatment for comorbidities

Children with acute lymphoblastic leukaemia (ALL) face a risk of infection from viral diseases like measles after completing chemotherapy, which could be mitigated by MMR vaccination. Results of a retrospective cross-sectional study in Saudi Arabia showed that of 57 children who survived ALL, 35 (61.4%) were seropositive, while 22 (38.6%) were seronegative [54]. Notably, children <5 years had higher rates of seronegativity and protection decreased with time since ALL treatment. Booster

vaccination resulted in a seroconversion of 57.1%. Similarly, in another study in the USA, among the 262 leukaemia, solid tumour, or brain tumour survivors, 110 (42%) tested negative for anti-measles IgG antibodies, while 152 (58%) tested positive [55]. A study involving 90 patients treated for ALL in Iran showed that seropositivity to measles was achieved if MMR was administered ≥3 months after chemotherapy [56]. Similarly, a study in China analysed clinical data from 110 children who completed chemotherapy and were subsequently revaccinated with the MMR vaccine[57]. Overall, 70 children were seronegative after chemotherapy. The mean measles antibody titres were 254.4±67.46 mIU/mL at baseline and increased to 1471.0±210.0 mIU/mL and 1872.0±262.1 mIU/mL at 1- and 6-months post-vaccination, but decreased to 1710.0±238.6 mIU/mL at 12 months.

In a cohort study, 19 liver transplant recipients were vaccinated based on the seroprotection status and were followed up to 9 years post vaccination[58]. During the follow-up period, approximately half of the recipients lost their seroprotection likely due to biliary atresia, treatment with anti-rejection drugs, or MMR vaccination before transplantation. These studies highlight the need for periodic monitoring of antibody titres in children with immunocompromising conditions and the potential requirement for booster doses to maintain adequate antibody levels.

11. Gender

VE may vary between males and females [30, 59-61]. A study using samples from Iran's National Measles Laboratory found that the geometric mean anti-measles IgG antibody level was higher in females, at 554.9 mIU/mL, compared to 468.4 mIU/mL in males [59]. Madi et al conducted an age-stratified serological study in Kuwait with 1000 participants. [60]. In that study, females had a higher GMT of 5.5 IU/ml (95%CI:

5.9-5.0) compared to 4.7 IU/ml (95%CI: 5.2-4.3) in males. Similar observations were reported in other studies as well [30, 61]. Boys vaccinated at 11-13 months in Finland, had lower antibody concentrations compared to girls and increasing the age of vaccination appeared to improve antibody responses in boys [30]. This indicates that females may have a stronger immune response to the MV than males.

Risk of bias within studies

Risk of bias was low (80-100%) for most of the included studies. Only three cohort studies and one cross-sectional study showed medium risk of bias (50-79%). No other risks were identified and no studies were excluded based on this assessment.

Modelling the impact of malnutrition on VE

As discussed earlier, VE is implicitly influenced by the proportion of malnourished children under 5 years of age. Due to a limitation of data published after 2014, we utilised data before 2014 to explore this relationship. We based our analysis on VE data available for 5 regions in India, namely Kangra (Himachal Pradesh, 2006), Purulia (West Bengal; 2005, 2006), Surat (Gujarat, 2003) and Cuddalore (Tamil Nadu, 2004) from various cohort studies [62-64]. The proportion of severely malnourished children (below -2 SD) of the above states is obtained from the National Family Health Survey (NFHS) 5.

To understand the relationship between malnutrition and VE, we fit a simple linear regression model to the data. In **Figure 2** we present the fit of two linear models that we have implemented along with 95% CIs. The former corresponds to a standard simple linear regression model and later is a model where the intercept parameter is constrained to not exceed the baseline VE which we considered to be 98%. We

observe a decreasing trend in VE with an increase in undernourished percentage in both the model setups, but they vary in terms of magnitude of the slope parameter. For Model-1 the estimated coefficients of intercept and slope are (150.866, -2.036) and for the constrained model (Model-2) estimates are (98, -0.6541). The observed findings are statistically significant at 10% level of significance, suggesting moderate evidence of an inverse relationship between VE and undernourishment. However, further investigation with additional data is recommended to strengthen this result.

Furthermore, we use the results of Model-2 to estimate a possible decrease in VE due to undernutrition for all Indian states for a given proportion of undernourished children from (NFHS-5). The expected percentage decrease in VE due to malnutrition is calculated by multiplying the observed percentage of undernourished individuals by 0.6541, the slope estimate derived from Model 2. The results thus obtained for all the states and union territories of India are presented in **Figure 3**.



Figure 2. Relationship between vaccine effectiveness and percentage of undernourished children**.** Model fit and 95% confidence intervals for standard linear model (Model-1; left) and constrained linear model (Model-2; right).



Figure 3. Spatial distribution of percentage of undernourished children (left) and model estimated percentage decrease in VE due to undernourishment (right). E, east; N, north; VE, vaccine effectiveness [Shape file source: https://onlinemaps.surveyofindia.gov.in; Software: R]

Impact of VE on measles incidence

Although high vaccination coverage is essential, VE also plays a critical role in determining the extent of an epidemic outbreak. For illustration purposes, we use an SI-type epidemic model [19, 20] (details of the model are provided in the supplementary material) with an initial population size of 5×10^5, the estimates of α=0.97 and birth rate of 0.015/26 per bi-weekly period. The seasonal measles transmission rate β is taken from previous studies [65, 66]. Vaccine coverages are assumed to be constant over time, with (i) high coverage: 90% for the first dose and 85% for the second dose; (ii) medium coverage: 85% for the first dose and 75% for the second dose.

Some modelling studies assume high average VE in the range of 90-99% [20, 67]. However, VE may be significantly lower in certain regions. For instance, in South

East Asian regions, the VE is 77% [4, 27]. Our analysis compares a baseline scenario without vaccination to two different vaccination scenarios with average VE of 95% and 77%, of two doses respectively. **Figure 4** displays the cases averted over a span of 20 years. The findings indicate that while vaccination significantly reduces cumulative cases compared to the no-vaccination baseline, the effectiveness of the vaccine is also crucial. Specifically, for high coverage, a vaccine with 95% effectiveness can avert approximately 94.54% of cases, whereas a vaccine with 77% effectiveness can avert about 82.00% (black, **Figure 4**). Similarly, for medium coverage, a vaccine with 95% effectiveness can avert 91.07% of cases, whereas a vaccine with 77% effectiveness can avert about 77.83% (grey bars, **Figure 4**). This underscores the importance of VE in managing disease outbreaks and achieving global measles elimination targets.



Figure 4. Percentage of cases averted under two different vaccination coverage scenarios. High coverage (V_1 = 90%, V_2 = 85%) is represented by black bars, while medium coverage (V_1 = 85%, V_2 = 75%) is depicted by grey bars. The two bars on the left show results for 95% VE, and the two bars on the right represent outcomes with 77% VE. V1 and V2 refer to first and second doses, respectively.

DISCUSSION

This systematic review highlights several factors that may contribute to the reduced effectiveness of MV, which could eventually lead to outbreaks of measles reported in various parts of the world. An important factor to be considered in low-and-middle-income countries (LMIC) is malnutrition among children. Several studies reported that malnutrition was associated with low seroconversion rates in children receiving MV [23-27]. Similar observations have been reported for other vaccine-preventable diseases (VPD) such as rotavirus [68] and tetanus [69]. Malnourished children are at a greater risk of infections [70] and contribute to nearly half of the deaths in children <5 years of age globally [71]. In India, the mean prevalence of malnourished children was 7.56% between 2019-2021 [72]. Therefore, vaccination strategies in this population need to be considered carefully.

Furthermore, from our model fit, we noted that higher malnutrition could be a potential factor to lower VE. Also, variation in the malnutrition status at the country or state level may cause an associated variation in the VE. The simulation results of the SI epidemiological model illustrate that not only vaccine coverage but also VE plays a major part in disease transmission and future outbreaks. Modelling scenarios with higher VE may result in a more optimistic/misleading measles incidence scenario compared to lower VE. However, because actual VE may not be high across regions, region-specific VE should be considered to estimate measles incidence more accurately. Overestimating VE could also adversely impact the measles elimination deadlines.

Several other factors also have an effect on VE. Consistent with studies in other VPDs [15], genetics can play a role in determining the immune response to MV [52,

53]. The common SNPs in the CD46 and IFI44L genes and the DDX58 gene are associated with MV-specific immunity. Treatment for comorbidities such as cancer was also reported to impact VE. These studies report that chemotherapy resulted in seronegativity in vaccinated children [54, 57]. Therefore, booster doses or vaccination after chemotherapy has been recommended. A previous review has outlined the effects of other cancer therapies on vaccination and has provided points to consider for patients receiving vaccination [73]. Consistent with previous findings for other vaccines [15], several studies included in this analysis report that the immune response to MV is stronger in females than males outlining the role of gender in VE [30, 59-61]. In addition to patient-related factors, the storage and distribution of vaccines or cold-chain management also impacts measles VE with higher temperatures reducing vaccine potency.

The effect of some factors identified in our analysis including age, vaccine strain, and preterm birth on VE were either inconclusive or did not show an effect. Studies on the impact of age reported conflicting results with some studies suggesting comparable protection for two different age groups [29, 30] and different VE for vaccination at 9 months [33, 34], while others reported better or long-term VE when infants were vaccinated at 16-24 months versus <15 months [31, 32]. Different vaccine strains showed comparable effects on VE. Other studies showed that VE did not vary between children born preterm or full-term. Only limited studies were obtained for other factors such as the effect of toxins and were insufficient to draw a conclusion on their impact on VE.

Our study had few limitations. Due to a limited number of studies and available data as well as heterogeneity among the studies, a meta-analysis was not feasible. Additionally, since very limited published data on VE was available from India, we

carried out a regression analysis using data before 2014. The data on VE at the regional level in India and survey data on undernourished children provided a foundation for our analysis. As more data on VE and other potential factors become available, the application of advanced statistical tools will enable a deeper and more precise understanding of how these factors influence VE leading to more informed insights and effective interventions.

Overall, this analysis outlines some potential factors that may impact VE thereby laying the foundation for future work. One of the proposed areas to explore is to address malnutrition through nutritional supplementation programs and micronutrient supplementation, such as vitamin A, to strengthen the immune system of children in LMICs. In this context, various scenario analyses have been conducted to assess the impact of such nutritional programs in the reduction of measles incidence [74]. Furthermore, given the limited region-specific studies currently available on the impact of genetic factors on measles, additional studies in LMIC's are warranted. Moreover, from a modelling perspective, to better capture the dynamics of measles transmission, we plan to model VE as a function of the potential factors discussed in this work rather than being treated as constant.

In conclusion, understanding the underlying causes of variation in the VE and identifying geographical regions with lower VE is crucial for measles control and elimination. Thus, policymakers while deciding disease control measures and setting elimination targets will need to have a clear understanding of the variation in VE and the factors causing this variation.

FINANCIAL SUPPORT & SPONSORSHIP: Funding for this study was provided by the Bill & Melinda Gates Foundation (INV-044445).

CONFLICTS OF INTEREST: None

AUTHOR CONTRIBUTIONS:

SG, DK: Conceptualization, data curation, screening, analysis, epidemiological modelling, and writing. NM, Conceptualization, data curation, screening, analysis, and writing. SNS: Conceptualization, data curation, screening, analysis, writing, editing and formatting. ADR: Reviewing. SM: Conceptualization, supervising, writing and reviewing. All authors read and approved the final draft of the manuscript.

REFERENCES

[1] Hübschen JM, Gouandjika-Vasilache I, Dina J (2022) Measles. Lancet 399:678-90.
[2] Measles cases surge worldwide, infecting 10.3 million people in 2023. World Health Organization. 2024. Available at https://www.who.int/news/item/14-11-2024-measles-cases-surge-worldwide--infecting-10.3-million-people-in-2023. Accessed February 3, 2025.
[3] Measles fact sheets. World Health Organization. Available at https://www.who.int/news-room/fact-sheets/detail/measles. Accessed August 15, 2024.
[4] Uzicanin A, Zimmerman L (2011) Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis 204 Suppl 1:S133-48.
[5] Wong BK, Fadel SA, Awasthi S, Khera A, Kumar R, Menon G, Jha P (2019) The impact of measles immunization campaigns in India using a nationally representative sample of 27,000 child deaths. Elife 8.
[6] Measles vaccination coverage, World Health Organization. Available at https://immunizationdata.who.int/global/wiise-detail-page/measles-vaccination-coverage?CODE=IND&ANTIGEN=MCV1&YEAR= Accessed: December 20, 2024.
[7] Suvvari TK, Kandi V, Mohapatra RK, Chopra H, Islam MA, Dhama K (2023) The re-emergence of measles is posing an imminent global threat owing to decline in its vaccination rates amid COVID-19 pandemic: a special focus on recent outbreak in India - a call for massive vaccination drive to be enhanced at global level. Int J Surg 109:198-200.
[8] Vaidyanathan G (2022) Massive measles outbreak threatens India's goal to eliminate disease by 2023. Nature.
[9] Vaccine efficacy, effectiveness and protection. 2021. Available at https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection Accessed: December 20, 2024.
[10] Endalamaw D, Nibret E, Munshea A, Mekonnen F, Tadesse S, Zeru T, Tefera M, Yismaw G (2024) Measles vaccine effectiveness in African children: a systematic review and meta-analysis. BMC Infect Dis 24:1330.
[11] Finan C, Ota MO, Marchant A, Newport MJ (2008) Natural variation in immune responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian infants. PLoS One 3:e3485.
[12] Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, Griffin DE (2007) Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 196:1339-45.
[13] Nakaya HI, Hagan T, Duraisingham SS, Lee EK, Kwissa M, Rouphael N, Frasca D, Gersten M, Mehta AK, Gaujoux R, Li GM, Gupta S, Ahmed R, Mulligan MJ, Shen-Orr S, Blomberg BB, Subramaniam S, Pulendran B (2015) Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures. Immunity 43:1186-98.
[14] Ritz N, Mui M, Balloch A, Curtis N (2013) Non-specific effect of Bacille Calmette-Guérin vaccine on the immune response to routine immunisations. Vaccine 31:3098-103.
[15] Zimmermann P, Curtis N (2019) Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev 32.

[16] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71.
[17] Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO Expert Committee on Biological Standardization Sixty-seventh report. Available at https://cdn.who.int/media/docs/default-source/prequal/vaccines/who-trs-1004-web-annex-9.pdf. Accessed December 20, 2024.
[18] Barker TH, Stone JC, Sears K, Klugar M, Tufanaru C, Leonardi-Bee J, Aromataris E, Munn Z (2023) The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evidence Synthesis 21:494-506.
[19] Finkenstädt BF, Grenfell BT (2002) Time Series Modelling of Childhood Diseases: A Dynamical Systems Approach. Journal of the Royal Statistical Society Series C: Applied Statistics 49:187-205.
[20] Thakkar N, Gilani SSA, Hasan Q, McCarthy KA (2019) Decreasing measles burden by optimizing campaign timing. Proc Natl Acad Sci U S A 116:11069-73.
[21] Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, Ezzati M, Grantham-McGregor S, Katz J, Martorell R, Uauy R (2013) Maternal and child undernutrition and overweight in low-income and middle-income countries. The Lancet 382:427-51.
[22] Griffin DE (2010) Measles virus-induced suppression of immune responses. Immunol Rev 236:176-89.
[23] Zahraei SM, Izadi S, Mokhtari-Azad T (2016) Factors affecting the seroconversion rate of 12-month-old babies after the first injection of measles vaccine in the southeast of Iran. Hum Vaccin Immunother 12:3118-24.
[24] Doshi RH, Mukadi P, Shidi C, Mulumba A, Hoff NA, Gerber S, Okitolonda-Wemakoy E, Ilunga BK, Muyembe JJ, Rimoin AW (2015) Field evaluation of measles vaccine effectiveness among children in the Democratic Republic of Congo. Vaccine 33:3407-14.
[25] Sánchez-Alemán MA, Gutiérrez-Pérez IA, Díaz-Salgado N, Zaragoza-García O, Olamendi-Portugal M, Castro-Alarcón N, Parra-Rojas I, Guzmán-Guzmán IP (2021) Low Seroprevalence of Measles-Specific IgG in Children of Three Ethnic Groups from Mexico: Influence of Age, Sex, Malnutrition and Family Size. Vaccines (Basel) 9.
[26] Ferreira MS, Cardoso MA, Mazzucchetti L, Sabino EC, Avelino-Silva VI (2023) Factors associated with incomplete vaccination and negative antibody test results for measles, mumps, and hepatitis A among children followed in the MINA-BRAZIL cohort. Rev Inst Med Trop Sao Paulo 65:e16.
[27] Yadav RM, Gomare M, Gaikwad A, Waghmare U, Betodkar U, Vashi MD, Kamal VK, Thangaraj JWV, Bangar S, Bhatnagar T, Murhekar M (2024) Interplay of missed opportunity for vaccination and poor response to the vaccine led to measles outbreak in a slum area of Eastern Mumbai, India. Epidemiol Infect 152:e56.
[28] Bati MG, Mulleta D, Deresa W, Gurmesa B. Assessment of Factors Associated with Low Measles Vaccine Effectiveness in Honkolo-Wabe District, Ethiopia. 2021.
[29] He H, Chen E, Chen H, Wang Z, Li Q, Yan R, Guo J, Zhou Y, Pan J, Xie S (2014) Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children. Vaccine 32:4001-5.

[30] Kontio M, Palmu AA, Syrjänen RK, Lahdenkari M, Ruokokoski E, Davidkin I, Vaarala O, Melin M (2016) Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months. J Infect Dis 213:2005-13.
[31] Geier DA, Kern JK, Geier MR (2019) Childhood MMR vaccination and the incidence rate of measles infection: a ten year longitudinal cohort study of American children born in the 1990s. BMC Pediatr 19:325.
[32] Bianchi FP, Stefanizzi P, De Nitto S, Larocca AMV, Germinario C, Tafuri S (2020) Long-term Immunogenicity of Measles Vaccine: An Italian Retrospective Cohort Study. J Infect Dis 221:721-8.
[33] Martins CL, Benn CS, Andersen A, Balé C, Schaltz-Buchholzer F, Do VA, Rodrigues A, Aaby P, Ravn H, Whittle H, Garly ML (2014) A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. J Infect Dis 209:1731-8.
[34] Malshe N, Palkar S, Kulkarni R, Lalwani S, Mishra AC, Arankalle V (2019) Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants. Vaccine 37:1443-8.
[35] World Health Organization. Measles vaccines: WHO position paper – April 2017. Weekly Epidemiological Record. 92(17), 205-227. Available at: https://iris.who.int/bitstream/handle/10665/255149/WER9217.pdf?sequence=1. Accessed August 8, 2024.
[36] Joshi J, Seth A, Aneja S, Singh AK, Aggarwal MK, Gupta N (2016) Rapid onset optic neuritis following measles vaccine in India: Case report. Vaccine Reports 6:86-8.
[37] Shah N, Parikh R, Casabona G, Kolhapure S (2017) A new combined vaccine against measles, mumps, rubella and varicella in India. Indian Pediatrics 54:1041-6.
[38] Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, Povey M, Da Costa C, Nicholson O, Innis BL (2014) Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12–15 Months. Journal of the Pediatric Infectious Diseases Society 4:339-48.
[39] Group M-S (2019) … dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity …. Human Vaccines & Immunotherapeutics.
[40] Klein NP, Lewis E, Fireman B, Hambidge SJ, Naleway A, Nelson JC, Belongia EA, Yih WK, Nordin JD, Hechter RC, Weintraub E, Baxter R (2015) Safety of Measles-Containing Vaccines in 1-Year-Old Children. Pediatrics 135:e321-e9.
[41] (2018) Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. Human Vaccines & Immunotherapeutics 14:2921-31.
[42] Griffin DE (2016) The Immune Response in Measles: Virus Control, Clearance and Protective Immunity. Viruses 8.
[43] Klein NP, Zerbo O, Goddard K, Wang W, Fohner AE, Wiesner A, Shokoohi V, Coller J, Bok K, Gans HA (2021) Genetic associations with a fever after measles-containing vaccines. Hum Vaccin Immunother 17:1763-9.
[44] National Vaccine Wastage Assessment (2018). Ministry of Health & Family Welfare, Government of India. Available at https://www.unicef.org/india/media/6686/file/National%20Vaccine%20Wastage%20Assessment.pdf. Accessed August 15, 2024.

[45] Dhanorkar, Abhaykumar B., and Govind Pandit Chaudhari. "Effective cold chain management system status for routine immunization in central Maharashtra." Int J Res Rev. 2018;5(1): 220-6.
[46] Measles vaccination. Vaccines & Immunizations. CDC. Available at https://www.cdc.gov/vaccines/vpd/measles/index.html. Accessed August 15, 2024.
[47] Carryn S, Feyssaguet M, Povey M, Di Paolo E (2019) Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up. Vaccine 37:5323-31.
[48] Musa S, Topalović B, Ćatić S, Smajlagić Z (2018) Assessment of vaccine effectiveness during measles outbreak in the Federation of Bosnia and Herzegovina, 2014-2015. Cent Eur J Public Health 26:79-82.
[49] Pillsbury A, Quinn H (2015) An assessment of measles vaccine effectiveness, Australia, 2006-2012. Western Pac Surveill Response J 6:43-50.
[50] Ferreira CSM, Perin M, Moraes-Pinto MI, Simão-Gurge RM, Goulart AL, Weckx LY, Dos Santos AMN (2018) Humoral immune response to measles and varicella vaccination in former very low birth weight preterm infants. Braz J Infect Dis 22:41-6.
[51] Jusko TA, Singh K, Greener EA, Oktapodas Feiler M, Thevenet-Morrison K, Lawrence BP, Wright RO, Thurston SW (2019) Blood Lead Concentrations and Antibody Levels to Measles, Mumps, and Rubella among U.S. Children. Int J Environ Res Public Health 16.
[52] Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Zimmermann MT, Grill DE, Schaid DJ, Poland GA (2017) Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine. Hum Genet 136:421-35.
[53] Ovsyannikova IG, Salk HM, Larrabee BR, Pankratz VS, Poland GA (2014) Single-nucleotide polymorphism associations in common with immune responses to measles and rubella vaccines. Immunogenetics 66:663-9.
[54] Fouda AE, Kandil SM, Boujettif F, Salama YS, Fayea NY (2018) Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination. Hematology 23:590-5.
[55] Crom DB, Walters LA, Li Y, Liang J, Hijano DR, Mulrooney DA, Carmichael LA, Ford SL, Andrews SJ, Smith D, Hudson MM, Mandrell BN (2024) Seroprevalence of Measles (Rubeola) Antibodies in Childhood Cancer Survivors. J Pediatr Hematol Oncol Nurs:27527530231221145.
[56] Koochakzadeh L, Khosravi MH, Pourakbari B, Hosseinverdi S, Aghamohammadi A, Rezaei N (2014) Assessment of immune response following immunization with DTP/Td and MMR vaccines in children treated for acute lymphoblastic leukemia. Pediatr Hematol Oncol 31:656-63.
[57] Wang M, Yuan Q, Deng PF, Fei Y, Zhang H, Zhou F, Chen WJ, Cao Q, Chen J, Gao YJ (2023) Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis. World J Pediatr 19:1062-70.
[58] Pittet LF, Gualtieri R, Verolet CM, L'Huillier AG, Wildhaber BE, McLin VA, Posfay-Barbe KM (2024) Long-term persistence of seroprotection against measles following measles-mumps-rubella vaccination administered before and after pediatric liver transplantation. Am J Transplant.
[59] Ghafoori F, Mokhtari-Azad T, Foroushani AR, Farahmand M, Shadab A, Salimi V (2024) Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory. BMC Infect Dis 24:696.

[60] Madi N, Altawalah H, Alfouzan W, Al-Nakib W, Al-Roumi E, Jeragh A (2020) Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy. J Med Virol 92:963-70.
[61] Tomášková H, Zelená H, Kloudová A, Tomášek I (2018) Serological survey of measles immunity in the Czech Republic, 2013. Cent Eur J Public Health 26:22-7.
[62] Desai V, Kapadia S, Kumar P, Nirupam S (2003) Study of measles incidence and vaccination coverage in slums of Surat city. Indian Journal of Community Medicine 28:10.
[63] Mohan A, Murhekar MV, Wairgkar NS, Hutin YJ, Gupte MD (2006) Measles transmission following the tsunami in a population with a high one-dose vaccination coverage, Tamil Nadu, India 2004–2005. BMC Infectious Diseases 6:143.
[64] Murhekar MV, Hutin YJ, Ramakrishnan R, Ramachandran V, Biswas AK, Das PK, Gupta SN, Maji D, Martolia HCS, Mohan A, Gupte MD (2011) The Heterogeneity of Measles Epidemiology in India: Implications for Improving Control Measures. The Journal of Infectious Diseases 204:S421-S6.
[65] Bjørnstad ON, Finkenstadt BF, Grenfell BT. Dynamics of measles epidemics: scaling noise, determinism, and predictability with the TSIR model. Ecological Monographs. 2002;72(2):185–202.
[66] Jandarov R, Haran M, Bjørnstad O, Grenfell B (2013) Emulating a Gravity Model to Infer the Spatiotemporal Dynamics of an Infectious Disease. Journal of the Royal Statistical Society Series C: Applied Statistics 63:423-44.
[67] Verguet S, Johri M, Morris SK, Gauvreau CL, Jha P, Jit M (2015) Controlling measles using supplemental immunization activities: A mathematical model to inform optimal policy. Vaccine 33:1291-6.
[68] Burnett E, Parashar UD, Tate JE (2021) Rotavirus Infection, Illness, and Vaccine Performance in Malnourished Children: A Review of the Literature. Pediatr Infect Dis J 40:930-6.
[69] Brüssow H, Sidoti J, Dirren H, Freire WB (1995) Effect of malnutrition in Ecuadorian children on titers of serum antibodies to various microbial antigens. Clinical Diagnostic Laboratory Immunology 2:62-8.
[70] Katona P, Katona-Apte J (2008) The interaction between nutrition and infection. Clin Infect Dis 46:1582-8.
[71] Malnutrition, World Health Organization. 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/malnutrition. Accessed August 14, 2024.
[72] Ulahannan SK, Wilson A, Chhetri D, Soman B, Prashanth NS (2022) Alarming level of severe acute malnutrition in Indian districts. BMJ Glob Health 7.
[73] Einarsson J, Wilkinson AN (2022) Vaccination considerations for patients receiving cancer therapy. Can Fam Physician 68:751-2.
[74] Noori N, Skrip LA, Oron AP, McCarthy KA, Proctor JL, Chabot-Couture G, Althouse BM, Phelan KPQ, Trehan I (2022) Potential Impacts of Mass Nutritional Supplementation on Measles Dynamics: A Simulation Study. Am J Trop Med Hyg 107:863-72.